BeOne Medicines (ONC) News
NASDAQ: ONCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
354.47+4.34 (+1.24%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ONC news summary
We found 29 recent headlines mentioning BeOne Medicines (ONC): 0 in the past week and 1 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, ONC is up 1.24% at $354.47. The most recent story, "BeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript", was published by Seeking Alpha on Sep 14, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest BeOne Medicines headlines
- BeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaONC, MS
- Stocks with the lowest short interest on Wall StreetSeeking Alpha
- Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized DrugmakersTrump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.NasdaqTEVA, BBIO, ONC
- Generative "AI" Macro Data Shows U.S. ImpactsThere are solid gains to knowledge workers. But smaller ones outside it.NasdaqADM, CLS, ONC
- BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?Does BeOne Medicines Ltd. - Sponsored ADR (ONC) have what it takes to be a top stock pick for momentum investors? Let's find out.Nasdaq
- BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy?Is it a good or bad thing when a stock experiences a golden cross technical event?Nasdaq
- BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- BeOne Medicines Q2 Earnings Call Highlights4 Stocks With Huge Cash Holdings at Silicon Valley BankBeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up…Nasdaq
- BeOne Medicines AG (ONC) Q2 2026 Earnings Call TranscriptSeeking Alpha
- BeOne Medicines AG 2026 Q2 - Results - Earnings Call PresentationSeeking Alpha
- BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesWhile the top- and bottom-line numbers for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some…Nasdaq
- Countdown to BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPSLooking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Sponsored ADR (ONC), delve into some of its key metrics to gain a deeper insight into the company's…Nasdaq
- BeOne Medicines: Owning The Full B-Cell Treatment SequenceSeeking Alpha
- Noteworthy ETF Outflows: FBT, ONC, HALO, NEOLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust NYSE Arca Biotechnology Index Fund (Symbol: FBT) where we…NasdaqFBT, ONC, HALO, NEO
- BeOne Medicines Expands U.S. Manufacturing With $1 Billion Investment(RTTNews) - BeOne Medicines Ltd. (ONC) announced a $300 million expansion of its flagship manufacturing and R&D center at the Princeton West Innovation Campus in Hopewell, New Jersey, bringing its…Nasdaq
- A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive PositionKey PointsCEO John Oyler sold nearly 110,000 American Depositary Shares for $34.6 million at a weighted average price of $315.28 per share.Nasdaq
- Kymera Appoints Felix Baker As Board Chairman, Succeeds Bruce Booth(RTTNews) - Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharmaceutical company, announced the appointment of Felix J. Baker as Chairman of the Board of Directors. He succeeds Bruce Booth,…NasdaqBCYC, KNSA, KOD, KYMR
- RSI Alert: BeOne Medicines (ONC) Now OversoldLegendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a…Nasdaq
- BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking AlphaONC, GS
- BeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?BeOne Medicines Ltd. - Sponsored ADR (ONC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in…Nasdaq
- BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO - SlideshowSeeking Alpha
- BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO TranscriptSeeking Alpha
- BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 34 Stocks With Huge Cash Holdings at Silicon Valley BankBeOne Medicines (NASDAQ:ONC) used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology,…Nasdaq
- BeOne Medicines AG (ONC) Q1 2026 Earnings Call TranscriptSeeking Alpha
- BeOne Medicines AG 2026 Q1 - Results - Earnings Call PresentationSeeking Alpha
- Tracking Baker Brothers Portfolio - Q4 2025 UpdateSeeking Alpha
- BeOne Medicines: Guidance Weighs But Multiple Catalysts In 2026Seeking Alpha
- BeOne Medicines AG (ONC) Q4 2025 Earnings Call TranscriptSeeking Alpha
- BeOne Medicines AG 2025 Q4 - Results - Earnings Call PresentationSeeking Alpha